Meditation for mental health: a dosing guide for general practice

Meditation is a family of attentional training practices — mindfulness, mantra, body scan, open awareness — shown in randomised trials to produce measurable reductions in anxiety, depression, and stress when practised at adequate dose. In Australian general practice, meditation occupies a specific niche: it is an evidence-based adjunct for mild-to-moderate presentations, a first-line option for depressive relapse prevention, and a practical tool where access to structured psychological therapies is limited by cost or geography.

The evidence base is real but requires precise reading. The 2014 AHRQ-commissioned meta-analysis by Goyal and colleagues (JAMA Internal Medicine) — 47 randomised controlled trials, 3,515 participants — found moderate-strength evidence that 8-week mindfulness programmes reduce anxiety (effect size 0.38 at 8 weeks), depression (0.30), and pain (0.33). Effect sizes are small-to-moderate and comparable to active controls, not superior to them. Meditation is a genuine option alongside exercise and psychological therapies, not a replacement for them.

For Australian GPs, the practical question is not “does meditation work” but “for which patient, in which form, at what dose, and how do I access it for them.”

A. Core clinical — the AU general-practice framework

Assessing suitability

Before prescribing meditation, take a focused mental health history:

• Indication — anxiety (GAD, health anxiety, panic), depressive episodes, stress, chronic pain, insomnia, PTSD, hypertension, generally impaired wellbeing
• Severity — mild-to-moderate presentations are the target range for meditation as primary adjunct; moderate-to-severe presentations require guideline-aligned care (CBT plus SSRI) as the primary strategy, with meditation layered on top
• Prior experience — patients who have tried and stopped meditation usually had inadequate dose (under 10 minutes, inconsistent) or chose an unsuitable modality for their presentation
• Psychotic or manic history — relative contraindication (see below)

Use validated measures at baseline and review: GAD-7 (anxiety), PHQ-9 (depression), K10 (general psychological distress), PSQI (sleep quality), pain VAS as relevant. Review at 4 and 8 weeks — the minimum dose window in most efficacious trials.

Contraindications and cautions

• Active psychosis or mania — defer; deep relaxation and open-awareness practices can reduce psychological defences and surface delusional or manic content. Resume after stabilisation with treating psychiatrist input
• Severe dissociative PTSD — standard mindfulness body-scan and open-awareness practices can precipitate flashbacks and dissociation; use trauma-sensitive approaches (see Special Populations below) or defer
• Active suicidal ideation — meditation is not a crisis intervention; stabilise through Lifeline (13 11 14), Community Mental Health, or emergency services first, then introduce
• Acute OCD — some patients find open-monitoring practices increase rumination; use focused-attention variants (breath or mantra) only, under psychologist guidance

Britton and colleagues (Clinical Psychological Science 2021) found that challenging experiences occur in 10–25% of regular meditators (transient anxiety, depersonalisation, intrusive imagery, somatic reactivity) and are functionally impairing in approximately 1–3%. Screen for trauma, psychotic vulnerability, and prior adverse reactions before prescribing. Counsel patients that practice intensity may temporarily increase before settling, and to return if distress escalates.

Dosing ladder

The dose-response signal across the literature is consistent: 8 weeks at 20 or more minutes of formal practice per day is the threshold most reliably linked to clinically meaningful symptom change. The starter dose most patients adhere to is 10 minutes per day. Progression:

• Weeks 1–2: 10 minutes/day, same time daily (pre-coffee morning or early-evening transition)
• Weeks 3–4: 15 minutes/day; re-assess GAD-7 and PHQ-9
• Weeks 5–6: 20 minutes/day
• Weeks 7+: 20–30 minutes/day maintenance

If a patient is not at 20 minutes/day by week 6, extend the titration rather than abandoning. Pizzoli and colleagues (Scientific Reports 2021) showed measurable mood and autonomic improvement at 10 minutes/day for 4 weeks — enough clinical signal to continue.

Modality matching

Clinical context	First-choice modality	Access
Mild–moderate anxiety or stress	App-based mindfulness	Smiling Mind (free, AU-developed)
Depressive relapse prevention (≥3 prior episodes, stable)	MBCT (8-week programme)	Clinical psychologist via Better Access MHCP
Hypertension adjunct	Transcendental Meditation	tm.org.au (paid; AUD 1,500–2,500)
Chronic pain	MBSR (8-week in-person or online)	Openground, university psychology programmes
Limited access due to geography or cost	App-based	Smiling Mind first; Headspace or Calm second

B. Evidence base — what the trials actually show

MBSR and MBCT

The Goyal 2014 meta-analysis remains the reference point for general mindfulness effects: 47 RCTs, 3,515 participants, moderate-strength evidence for small-to-moderate reductions in anxiety (ES 0.38), depression (ES 0.30), and pain (ES 0.33) at 8 weeks. Effects attenuate but persist at 3–6 months (0.20–0.22). Critically, meditation was not superior to other active treatments — exercise and CBT produced comparable effects. This positions meditation correctly: a genuine option, not a superior treatment.

MBCT for depressive relapse prevention has its own robust evidence base. The Kuyken PREVENT trial (Lancet 2015) — 212 adults with three or more prior depressive episodes — showed MBCT with antidepressant taper non-inferior to maintenance antidepressant over 24 months (relapse rate 44% vs 47%). NICE and the RANZCP Mood Disorders Clinical Practice Guideline 2020 acknowledge MBCT in maintenance-phase management. MBCT is the strongest indication for meditation in general practice — it changes the trajectory of a chronic relapsing condition for patients who prefer to avoid or cannot tolerate long-term antidepressants.

App-based mindfulness

Spijkerman and colleagues (Clinical Psychology Review 2016) — 15 RCTs, 2,360 participants — found online mindfulness produces small-to-moderate effects on depression (g=0.29), anxiety (g=0.22), and stress (g=0.51). App-based programmes produce comparable short-term outcomes to in-person delivery but show 30–50% lower retention at 3 months. The practical implication for GPs: prescribe an app as the default first step where access, cost, or geography makes in-person programmes impractical; pair with a 4-week GP review to sustain engagement.

The RANZCP Anxiety Disorders Clinical Practice Guideline 2018 supports mindfulness-based interventions as adjuncts for mild GAD. They do not replace CBT or SSRI for moderate-to-severe presentations.

C. Prescribing in practice

The beginner prescription template

Rx Meditation. Smiling Mind — Adult Foundations programme — 10 minutes per day, same time every day. Review at 4 weeks with GAD-7 and PHQ-9. Titrate to 20 minutes per day by week 6. Pair with one structural anchor: a calendar block, a pre-meal ritual, or a phone-free first 10 minutes of the day.

App recommendations for Australian patients

Smiling Mind is the default first-line prescription: AU-developed, free, not-for-profit, with an RACGP partnership and curriculum covering adults, children, workplace, and sleep. Headspace (~AUD 95/year) suits patients wanting a structured beginner-to-intermediate progression. Calm (~AUD 80/year) offers a broader content library and is good for patients who want more variety. Insight Timer (free tier) has an extensive library but variable quality — recommend specific playlists rather than free browsing. Waking Up (~AUD 150/year) suits patients who want secular, philosophically grounded content delivered without spiritual framing.

Structured programmes in Australia

MBSR (8 weeks, 20–45 minutes/day home practice) is available through Openground and the Melbourne Academic Mindfulness Interest Group (MAMIG). Cost is typically AUD 500–800; some private health-fund extras partially rebate under “health management.”

MBCT is primarily delivered through clinical psychologists with MBCT training, accessible via the Better Access Mental Health Treatment Plan pathway (10 individual psychology sessions per calendar year under MBS items 2715/2717). When making a MHCP referral, ask specifically whether the psychologist is trained in MBCT, as not all are.

Transcendental Meditation — tm.org.au — proprietary, AUD 1,500–2,500, the only modality with an American Heart Association Class IIB recommendation for adjunctive blood-pressure reduction (~4–5 mmHg systolic). Commercial-research conflict of interest and cost limit its role to patients specifically seeking a hypertension adjunct who are willing to commit financially and behaviourally.

D. Australian operations

MBS pathway

Standard GP consults (item 23 Level B, item 36 Level C) for initial assessment and prescription review. A Mental Health Care Plan — item 2715 (≥20 minutes) or item 2717 (≥40 minutes) preparation — is appropriate where meditation is one element of a plan for anxiety, depression, or PTSD; this unlocks 10 Better Access psychology sessions per calendar year. Review via item 2712 at 4–8 weeks.

Where meditation is part of a chronic-condition plan (hypertension, chronic pain, T2DM with comorbid anxiety), the GP Chronic Condition Management Plan (item 965) is appropriate.

DVA Gold and White Card holders — meditation-based therapy is accessible through DVA-funded providers. Open Arms (1800 011 046) supports veterans and families with PTSD, anxiety, and chronic stress.

Telehealth — MHCP preparation and review meet the existing-relationship and 12-month rule; phone tier is acceptable for review, video preferred for initial assessment.

Medico-legal considerations

When prescribing meditation as the sole strategy for moderate-to-severe mental illness, document the patient’s informed preference, the alternatives offered, and the review interval. Meditation as an adjunct alongside guideline-aligned care carries no specific medico-legal concern beyond standard documentation.

E. Special populations

Older adults. Meditation is well-tolerated and accessible across older age groups. Some older adults prefer secular guided-audio formats and shorter sessions (10–15 minutes). Walking meditation in frail or balance-impaired patients carries a falls risk — use seated or supine formats instead. Cholinergic burden from concurrent anticholinergic medications does not interact with meditation practice itself.

Pregnancy. Mindfulness-based programmes are non-pharmacological, evidence-supported for antenatal anxiety and depression, and appropriate as first-line where medication is declined or deferred. COPE — Centre of Perinatal Excellence provides pregnancy-specific resources and clinician referral pathways. Supine body-scan practices should be modified to left-lateral position after 20 weeks to avoid aortocaval compression; seated or reclined formats are the default for third-trimester patients.

PTSD and trauma history. Standard mindfulness practices — particularly body-scan and open-awareness phases — can precipitate flashbacks, dissociation, or intrusive imagery in trauma-exposed patients. Phoenix Australia (Australian PTSD Treatment Guidelines 2020) recommends trauma-focused psychological therapies (Prolonged Exposure, CPT, EMDR) as first-line. Meditation can be a supportive adjunct after stabilisation when delivered with trauma-sensitive modifications (shortened body scan, eyes-open option, explicit consent, and a trauma-trained clinician scaffold). The iRest Institute offers a clinically validated trauma-aware lineage with specific PTSD adaptations.

Children and adolescents. Smiling Mind includes age-appropriate programmes from early childhood through adolescence with a research-aligned curriculum for anxiety and school-based wellbeing. Adolescents with school refusal or performance anxiety often respond well to 10-minute daily app-guided practice as a low-barrier first step. Longer guided programmes may suit adolescents already engaged in yoga or sport-based mindfulness.

When to escalate

Meditation alone is insufficient and referral or escalation is needed when:

• Depression, anxiety, or PTSD is moderate-to-severe — guideline-aligned care (CBT, SSRI/SNRI, specialist review) must be the primary strategy, with meditation as an adjunct only
• Suicidal ideation, self-harm, or acute crisis — immediate mental health assessment; Lifeline 13 11 14, Beyond Blue 1300 22 4636, or the nearest emergency department
• Symptoms are not improving after 8 weeks of adequate practice — reassess the diagnosis and add or escalate treatment
• Psychotic symptoms emerge or worsen during practice — stop meditation and refer urgently to a psychiatrist
• Comorbid substance-use disorder is driving mental health symptoms — addiction-focused treatment takes precedence
• A patient with known bipolar disorder develops hypomania, mixed states, or rapid cycling during meditation practice — hold and review with treating psychiatrist

What this article is and is not

This is general health information drawn from current Australian general practice and specialist guidelines — RANZCP Anxiety Disorders CPG 2018, RANZCP Mood Disorders CPG 2020, NPS MedicineWise, and the international trial literature. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific treatment — including whether to use meditation and at what dose — are made with your own GP and treating clinicians.

For Australian consumer-friendly resources: Smiling Mind, HealthDirect — Mindfulness, Better Health Channel.

For acute mental health crisis: Lifeline 13 11 14, Beyond Blue 1300 22 4636, or your nearest emergency department.

---

Sources cited

1. Goyal M et al. — Meditation programs for psychological stress and well-being (JAMA Intern Med 2014)
2. Kuyken W et al. — PREVENT trial: MBCT vs maintenance antidepressant (Lancet 2015)
3. Spijkerman MPJ et al. — Effectiveness of online mindfulness-based interventions (Clin Psychol Rev 2016)
4. Pizzoli SFM et al. — Brief mindfulness dose and HRV (Sci Rep 2021)
5. Britton WB et al. — Meditation-related adverse effects (Clin Psychol Sci 2021)
6. RANZCP 2018 Anxiety Disorders Clinical Practice Guideline
7. RANZCP 2020 Mood Disorders Clinical Practice Guideline
8. Phoenix Australia — Australian PTSD Treatment Guidelines 2020
9. RACGP
10. Therapeutic Guidelines (eTG) — Psychotropic
11. NPS MedicineWise
12. Smiling Mind
13. Openground MBSR Australia
14. Melbourne Academic Mindfulness Interest Group (MAMIG)
15. TM Australia
16. Open Arms — DVA Veterans and Families Counselling
17. iRest Institute — Trauma-informed yoga nidra
18. COPE — Centre of Perinatal Excellence
19. HealthDirect
20. Better Health Channel
21. Lifeline
22. Beyond Blue